MGRC Therapeutics and Dx&Vx Co. Ltd. Forge Strategic Collaboration for Genomic Testing Services

Advancing Genomic Analysis and Digital Healthcare in Malaysia and Beyond   

PETALING JAYA, 7 JUNE 2024 – Malaysian Genomics Resource Centre Berhad (“MGRC” or “the Group”), a leading genomics and biopharmaceutical specialist, is excited to announce the Group’s wholly-owned subsidiary MGRC Therapeutics Sdn. Bhd.(“MGRC Therapeutics”) has entered into a Strategic Collaboration Agreement (“SCA”) with Dx&Vx Co. Ltd. (“DXVX”), a prominent healthcare solutions provider based in the Republic of Korea and listed on KOSDAQ with a market capitalisation of 81.44 billion Korean Won (“KWR”) . This SCA aims to drive the development and supply of advanced genomic testing services, setting new benchmarks in the field of genomic analysis and digital healthcare.

Under this strategic alliance, MGRC Therapeutics will leverage its extensive expertise in genomics and biopharmaceuticals to support the operational and technical aspects of the genomic testing services. Concurrently, DXVX will provide its cutting-edge “GenomeCheck” solutions and technical consultancy to enhance the service offerings. This collaboration is a significant step towards entering the global market with genomic analysis services, aligning with both companies’ strategic goals to expand their reach and impact.

Azri Azerai, Executive Chairman of Malaysian Genomics expressed his enthusiasm for the agreement, stating, “Partnering with Dx&Vx Co. Ltd. is a strategic move that will elevate our genomic testing services to new heights. By combining our strengths, we are set to enhance the precision and accessibility of genomic analysis, making significant strides in personalised medicine. This collaboration reinforces our dedication to innovation and excellence in the healthcare sector.”

Kyu-chan Kwon, CEO of Dx&Vx Co. Ltd., commented on the collaboration, “This Strategic Collaboration Agreement with MGRC Therapeutics marks a pivotal moment for DXVX as we aim to establish a strong foothold in the Asian and global markets. Genomic analysis is a cornerstone of our Healthcare 4.0 vision, and through this collaboration, we are set to expand our genomic testing services and digital healthcare solutions, ultimately improving patient outcomes and advancing the field of preventive care.”

This collaboration underscores MGRC’s commitment to innovation and excellence in biopharmaceuticals and genomics. By combining MGRC Therapeutics’ production capabilities with DXVX’s technological advancements, the partnership is poised to significantly enhance the reach and effectiveness of genomic testing services, addressing the growing demand for sophisticated healthcare solutions.